

四庫全書




□兆■彥 ■□呂彌 •



卷之三



□ጀ■ን。 የ□■ኞ。 ┌




ମୁଖ୍ୟମନ୍ତ୍ରୀଙ୍କ ଦିଗ୍ନାୟକ ପତ୍ରରେ ମହାଶ୍ରମରେ ମହାଶ୍ରମରେ ମହାଶ୍ରମରେ



မြန်မာစာ ◆ ရှိုက်ပြု ◆



■□□○ණ●ම්‍යුණු රිජ්‍යාලි සංග්‍රහ මධ්‍ය ප්‍රතිපාදන මධ්‍ය ප්‍රතිපාදන



A horizontal row of icons used for file management or document representation. From left to right, the icons include: a folder with a document inside, a document with a checkmark, a document with a question mark, a document with a plus sign, a document with a minus sign, a document with a double arrow, a document with a single arrow, a document with a double arrow pointing down, and a document with a double arrow pointing up.

A horizontal row of 20 small icons representing various file types and applications, including documents, spreadsheets, images, and communication tools.

A horizontal row of twelve small, light-blue icons used for navigating through a software application. The icons include symbols for a hand cursor, a clipboard, a computer monitor, a yin-yang symbol, an envelope, a folder, a gear, a file cabinet, another yin-yang symbol, an envelope, a document, a gear, and a file cabinet.

L6 ANSWER 6 OF 43

HCAPLUS COPYRIGHT 2006 ACS on STN

Full	19980625
Text	19980625

ACCESSION NUMBER:

1998:479505 HCAPLUS

DOCUMENT NUMBER:

129:122870

TITLE:

Preparation of cycloalkyl, lactam, lactone and related compounds for inhibiting β -amyloid peptide release and/or its synthesis

INVENTOR(S):

Wu, Jing; Tung, Jay S.; Thorsett, Eugene D.; Pleiss, Michael A.; Nissen, Jeffrey S.; Neitz, Jeffrey; Latimer, Lee H.; John, Varghese; Freedman, Stephen; Britton, Thomas C.; Audia, James E.; Reel, Jon K.; Mabry, Thomas E.; Dressman, Bruce A.; Cwi, Cynthia L.; Droste, James J.; Henry, Steven S.; McDaniel, Stacey L.; Scott, William Leonard; Stucky, Russell D.; Porter, Warren J.

PATENT ASSIGNEE(S):

Athena Neurosciences, Inc., USA; Eli Lilly & Co.

SOURCE:

PCT Int. Appl., 889 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>WO 9828268</u>	A2	19980702	<u>WO 1997-US22986</u>	19971222
<u>WO 9828268</u>	A3	19981008		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
<u>ZA 9711537</u>	A	19980625	<u>ZA 1997-11537</u>	19971222
<u>CA 2272305</u>	AA	19980702	<u>CA 1997-2272305</u>	19971222
<u>AU 9857007</u>	A1	19980717	<u>AU 1998-57007</u>	19971222
<u>AU 749658</u>	B2	20020627		
<u>EP 951466</u>	A2	19991027	<u>EP 1997-953208</u>	19971222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
<u>CN 1242007</u>	A	20000119	<u>CN 1997-180901</u>	19971222
<u>BR 9714517</u>	A	20000704	<u>BR 1997-14517</u>	19971222
<u>JP 2000511932</u>	T2	20000912	<u>JP 1998-528867</u>	19971222
<u>NZ 335583</u>	A	20010330	<u>NZ 1997-335583</u>	19971222
<u>CN 1616432</u>	A	20050518	<u>CN 2004-10057888</u>	19971222
<u>TW 568914</u>	B	20040101	<u>TW 1997-86119638</u>	19971223
<u>MX 9905844</u>	A	20000731	<u>MX 1999-5844</u>	19990621
<u>NO 9903098</u>	A	19990820	<u>NO 1999-3098</u>	19990622
<u>US 2002045747</u>	A1	20020418	<u>US 2001-916282</u>	20010730
<u>US 2002055500</u>	A1	20020509	<u>US 2001-916440</u>	20010730
<u>US 6653303</u>	B1	20031125	<u>US 2003-336824</u>	20030106
<u>US 6667305</u>	B1	20031223	<u>US 2003-336745</u>	20030106
<u>US 6683075</u>	B1	20040127	<u>US 2003-336806</u>	20030106
<u>US 2004043977</u>	A1	20040304	<u>US 2003-336687</u>	20030106
<u>US 2004058900</u>	A1	20040325	<u>US 2003-336767</u>	20030106
<u>US 2005203080</u>	A1	20050915	<u>US 2003-733877</u>	20031212
<u>US 2005182046</u>	A1	20050818	<u>US 2004-777247</u>	20040213

<u>US 2005215541</u>	A1	20050929	<u>US 2004-951992</u>	20040929
<u>US 6951854</u>	B2	20051004		
<u>US 2005272666</u>	A1	20051208	<u>US 2004-1610</u>	20041202
<u>US 2006079499</u>	A1	20060413	<u>US 2004-1608</u>	20041202
<u>PRIORITY APPLN. INFO.:</u>				
			<u>US 1996-64851P</u>	P 19961223
			<u>US 1996-780025</u>	A1 19961223
			<u>US 1997-996422</u>	A3 19971222
			<u>WO 1997-US22986</u>	W 19971222
			<u>US 2001-915263</u>	A1 20010726
			<u>US 2001-915342</u>	A3 20010727
			<u>US 2001-915362</u>	A3 20010727
			<u>US 2001-915379</u>	A3 20010727
			<u>US 2001-915480</u>	A3 20010727
			<u>US 2001-915564</u>	A3 20010727
			<u>US 2001-916440</u>	A1 20010730
			<u>US 2003-336687</u>	B3 20030106
			<u>US 2003-336767</u>	A3 20030106

OTHER SOURCE(S): MARPAT 129:122870


AB Disclosed are compds. R1ZmNHYnCHpR2C(X)R3 [R1 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, or cycloalkenyl or aryl, heteroaryl, or heterocyclic; R2 and R3 form a cycloalkyl, cycloalkenyl, heterocyclic, substituted cycloalkyl, or substituted cycloalkenyl ring which is optionally fused; X = oxo, thioxo, hydroxyl, thiol, or hydro; Y = CHR4CONH where R4 = (un)substituted alkyl, alkenyl, or alkynyl or cycloalkyl, aryl, heteroaryl, or heterocyclic; Z is TCX'X''CO where T is a bond, O, S, NR5 (R5 = H, acyl, alkyl, aryl, or heteroaryl), X' and X'' are H, OH, or F or X'X'' = oxo; m, p = 0, 1; n = 0, 1, 2] which inhibit β -amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Thus, 3-[[N'-(3,4-methylenedioxyphenylacetyl)-L-alaninyl]amino]-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2-one was prep'd. by coupling of 3-(L-alaninylamino)-2,3-dihydro-1-methyl-5-phenyl-1H-1,4-benzodiazepin-2-one with 3,4-methylenedioxyphenylacetic acid.

IT 38559-92-1, 4-Benzoyloxyphenoxyacetic acid

RL: RCT (Reactant); RACT (Reactant or reagent)
(prep'n. of cycloalkyl, lactam, lactone and related compds. for inhibiting β -amyloid peptide release and/or its synthesis)

RN 38559-92-1 HCAPLUS

CN Acetic acid, [4-(phenylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 43 HCPLUS COPYRIGHT 2006 ACS on STN

Full
Text

ACCESSION NUMBER: 1999:654690 HCPLUS
 DOCUMENT NUMBER: 132:152100
 TITLE: Synthesis and antiproliferative activity of
 N-acylaspartic acid dimethyl esters
 AUTHOR(S): Schlitzer, Martin; Sattler, Isabel; Dahse, Hans-Martin
 CORPORATE SOURCE: Institut fur Pharmazeutische Chemie,
 Philipps-Universitat Marburg, Marburg, D-35032,
 Germany
 SOURCE: Anticancer Research (1999), 19(3A), 2117-2120
 PUBLISHER: International Institute of Anticancer Research
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB Farnesyl residues are found as a lipophilic modification of a no. of important proteins. In addn., synthetic farnesyl derivs. display a range of biol. effects. We have prepd. a series of N-acylaspartates as structural analogs of farnesylypyrophosphate in which the farnesyl residue has been replaced by a no. of different aliph. and arom. carboxylic acids and the aspartate is used as a pyrophosphate surrogate. The corresponding di-Me esters of these aspartates were assayed against different tumor cell lines. Several N-acylaspartic acid di-Me esters carrying an arom. acyl residue displayed a selective antiproliferative effect against THP-1 cells with GI₅₀ values ranging from 7.6 to 1.3 μM.

IT 38559-92-1

RL: RCT (Reactant); RACT (Reactant or reagent)
 (synthesis and antiproliferative activity of N-acylaspartic acid di-Me esters)

RN 38559-92-1 HCPLUS

CN Acetic acid, [4-(phenylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

23

THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

RC 201. A1A68


L6 ANSWER 29 OF 43 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text
Text

ACCESSION NUMBER: 1972:547506 HCAPLUS
 DOCUMENT NUMBER: 77:147506
 TITLE: Irreversible enzyme inhibitors. 195. Inhibitors of thymidine kinase from Walker 256 carcinoma derived from thymidine 5'-acetate
 AUTHOR(S): Baker, B. R.; Neenan, John P.
 CORPORATE SOURCE: Dep. Chem., Univ. California, Santa Barbara, CA, USA
 SOURCE: Journal of Medicinal Chemistry (1972), 15(9), 940-4
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Derivs. of thymidine 5'-acetate were good inhibitors of thymidine kinase [9002-06-6] from Walker 256 rat tumor, and may serve as prototypes for synthesis of more potent reversible and irreversible inhibitors for use as antitumor agents. The inhibition displayed was attributed in part to an interaction of the inhibitor with a hydrophilic region adjacent to the enzyme active site. Thymidine 5'- α -thionaphthoxyacetate (I) [36983-60-5] and thymidine 5'-p-benzylxyphenoxyacetate (II) [36983-61-6], the 2 most potent inhibitors tested, bound to the enzyme approx. as strongly as thymidine. Thymidine 5'-carbamate derivs. were inactive. I and II were prep'd. by coupling the appropriate carboxylic acid with thymidine in the presence of N,N'-dicyclohexylcarbodiimide.

IT 38559-92-1PRL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)RN 38559-92-1 HCAPLUS

CN Acetic acid, [4-(phenylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)



RSS, JS
Minowala


L6 ANSWER 19 OF 43 HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text
Text

ACCESSION NUMBER: 1992:531082 HCAPLUS
 DOCUMENT NUMBER: 117:131082
 TITLE: [(alkoxyphenyl)alkyl]- and
 [(alkylphenyl)alkyl]pyridines and -pyridine oxides,
 methods for their preparation and their use as
 antiallergic agents
 INVENTOR(S): Friebe, Walter Gunar; Kampe, Wolfgang; Linssen,
 Marcel; Wilhelms, Otto Henning
 PATENT ASSIGNEE(S): Boehringer Mannheim GmbH, Germany
 SOURCE: Ger. Offen., 12 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<u>DE 4038335</u>	A1	19920604	<u>DE 1990-4038335</u>	19901201
<u>CA 2099603</u>	AA	19920602	<u>CA 1991-2099603</u>	19911128
<u>WO 9209598</u>	A1	19920611	<u>WO 1991-EP2249</u>	19911128
W: AU, BG, BR, CA, CS, FI, HU, JP, KR, NO, PL, RO, SU, US RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
<u>AU 9189574</u>	A1	19920625	<u>AU 1991-89574</u>	19911128
<u>EP 559695</u>	A1	19930915	<u>EP 1991-920436</u>	19911128
<u>EP 559695</u>	B1	19970122		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
<u>JP 06503076</u>	T2	19940407	<u>JP 1992-500329</u>	19911128
<u>AT 148115</u>	E	19970215	<u>AT 1991-920436</u>	19911128
<u>ES 2097822</u>	T3	19970416	<u>ES 1991-920436</u>	19911128
<u>US 5399575</u>	A	19950321	<u>US 1993-66058</u>	19930614
<u>PRIORITY APPLN. INFO.:</u>			<u>DE 1990-4038335</u>	A 19901201
			<u>WO 1991-EP2249</u>	A 19911128

OTHER SOURCE(S): CASREACT 117:131082; MARPAT 117:131082
 GI



AB Certain [(alkoxyphenyl)alkyl]pyridines, [(alkylphenyl)alkyl]pyridines, or [(alkoxyphenyl)alkyl]pyridine 1-oxides or [(alkylphenyl)alkyl]pyridine 1-oxides are claimed. A process for their prepn. comprises, e.g., the alkylation of a [(hydroxyphenyl)alkyl]pyridine 1-oxide or the phenylation of a methylpyridine 1-oxide deriv. Pharmaceuticals contg. said pyridine derivs. and their use for the treatment of allergies are claimed. Alkylation of 4-[2-(4-hydroxyphenyl)ethenyl]pyridine with bromovaleronitrile gave 5-[4-[2-(4-pyridyl)ethenyl]phenoxy]valeronitrile (I) in 86 yield. The antiallergic activity of I was not tested.


IT 143052-54-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as allergy inhibitor)

RN 143052-54-4 HCAPLUS

CN Acetic acid, [4-[2-(4-pyridinyl)ethyl]phenoxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 43

HCAPLUS COPYRIGHT 2006 ACS on STN

Full Text	Abstract
-----------	----------

ACCESSION NUMBER: 1999:654690 HCAPLUS
 DOCUMENT NUMBER: 132:152100
 TITLE: Synthesis and antiproliferative activity of
 N-acylaspartic acid dimethyl esters
 AUTHOR(S): Schlitzer, Martin; Sattler, Isabel; Dahse, Hans-Martin
 CORPORATE SOURCE: Institut fur Pharmazeutische Chemie,
 Philipps-Universitat Marburg, Marburg, D-35032,
 Germany
 SOURCE: Anticancer Research (1999), 19(3A), 2117-2120
 PUBLISHER: International Institute of Anticancer Research
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB Farnesyl residues are found as a lipophilic modification of a no. of important proteins. In addn., synthetic farnesyl derivs. display a range of biol. effects. We have prep'd. a series of N-acylaspartates as structural analogs of farnesylypyrophosphate in which the farnesyl residue has been replaced by a no. of different aliph. and arom. carboxylic acids and the aspartate is used as a pyrophosphate surrogate. The corresponding di-Me esters of these aspartates were assayed against different tumor cell lines. Several N-acylaspartic acid di-Me esters carrying an arom. acyl residue displayed a selective antiproliferative effect against THP-1 cells with GI₅₀ values ranging from 7.6 to 1.3 μM.

IT 38559-92-1

RL: RCT (Reactant); RACT (Reactant or reagent)
 (synthesis and antiproliferative activity of N-acylaspartic acid di-Me esters)

RN 38559-92-1 HCAPLUS

CN Acetic acid, [4-(phenylmethoxy)phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

23

THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT